ABOS - NASDAQ

Acumen Pharmaceuticals, Inc.

ABOS·NASDAQ

$2.37

+2.6%

HealthcareBiotechnology

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$143.26M

EPS-2.0000

P/E Ratio-1.18

Earnings Date08/11/2026

abos

Total Equity

Last Annual Value

70.43M

3-Year CAGR

-28%

5-Year CAGR

42%

10-Year CAGR

23%

Adjust for Inflation

Acumen Pharmaceuticals, Inc. Competitors Analysis of Total Equity

ABOS · NASDAQ

Company	Total Equity	CAGR 3Y	CAGR 5Y	CAGR 10Y
Acumen Pharmaceuticals, Inc. NASDAQ:ABOS	70.43M	-35.9%	-20.7%	N/A
Seer, Inc. NASDAQ:SEER	259.31M	-13.2%	-12.4%	N/A
Actuate Therapeutics Inc NASDAQ:ACTU	7.92M	N/A	N/A	N/A
C4 Therapeutics, Inc. NASDAQ:CCCC	256.59M	1.4%	-8.0%	N/A
PepGen Inc. NASDAQ:PEPG	147.44M	10.8%	2.1%	N/A
Instil Bio, Inc. NASDAQ:TIL	113.87M	-20.4%	-27.2%	N/A
Tevogen Bio Holdings Inc. NASDAQ:TVGN	-6.67M	N/A	N/A	N/A
Agenus Inc. NASDAQ:AGEN	-277.86M	N/A	N/A	N/A
VistaGen Therapeutics, Inc. NASDAQ:VTGN	70.39M	79.9%	-5.2%	N/A
Alector, Inc. NASDAQ:ALEC	30.65M	-38.9%	-36.7%	N/A
Inovio Pharmaceuticals, Inc. NASDAQ:INO	24.10M	-41.0%	-43.0%	-15.1%

Acumen Pharmaceuticals, Inc. Fair Value Envelope

ABOS · NASDAQ

Our analysis suggests that ABOS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.365, this represents a potential HIDDEN relative to our calculated worth for Acumen Pharmaceuticals, Inc..

HIDDEN

Intrinsic Value

Current Price: $2.365

Related Guides

Blog Categories

Continue your ABOS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.